Proposed psilocybin–c-Fos–SIRT6 axis: a framework, not a validated therapy
The abstract proposes a molecular framework linking psilocybin to c-Fos, SIRT6 and DNA repair, with simulations of periodic micro-dosing; it reports no human outcomes and no validated product. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract proposes that psilocybin and psilocin drive c-Fos expression, which transactivates SIRT6, linking this to DNA repair and reduced inflammatory signaling. [1]
A four-variable mathematical model and numerical simulations suggest periodic micro-dosing restores a genomic DNA integrity score to youthful levels. [1]
The abstract cites prior experimental work in aged murine models reporting extended cellular lifespan and improved overall survival with psilocybin treatment. [1]
The source at a glance
- Study type / format
- Abstract of a proposed mechanistic framework with mathematical modeling and numerical simulation
- Population / context
- Aged murine models (cited prior work) and a proposed molecular framework; no human participants described.
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- October 9, 2026
Proposed axis from psilocybin to SIRT6
The authors describe a proposed molecular paradigm: psilocybin and its active metabolite psilocin drive broad c-Fos expression, and nuclear c-Fos is said to transactivate the SIRT6 promoter. Elevated SIRT6 is linked in this framework to histone H3 lysine 9 deacetylation, recruitment of DNA double-strand break repair machinery, repression of NF-kB inflammatory signaling and reduced senescence-associated secretion. These are proposed mechanisms, not demonstrated causal human effects.
Supporting source [1]
Simulated micro-dosing and exercise combination
The abstract reports a four-variable mathematical model of psilocin pharmacokinetics, c-Fos induction, SIRT6 transactivation and DNA repair, yielding a Psilocybin Longevity Index. Numerical simulations are said to show that periodic micro-dosing restores a genomic DNA integrity score to youthful levels. Combining chemical 5-HT2A stimulation with aerobic exercise is proposed as a dual-mode SIRT6 activation shield. These are simulation and proposal results, not measured human lifespan or clinical benefits.
Supporting source [1]
Preclinical basis and abstract-only scope
The abstract refers to prior experimental work in aged murine models, where psilocybin treatment reportedly extended cellular lifespan and improved overall survival. It frames the new work as a biochemical and mathematical foundation for non-hallucinogenic 5-HT2A geroprotective therapeutics and precision epigenetic age-reversal platforms. Only the abstract was reviewed; the full text was not reviewed, so methods, sample sizes, follow-up and limitations cannot be checked.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The mechanisms are proposed, the micro-dosing results come from numerical simulations, and the survival findings are attributed to prior work in aged murine models, not humans. No clinical outcomes, dosing or validated product are reported.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Lakshmanane B. · europepmc.org · October 9, 2026